Results 261 to 270 of about 2,311,361 (335)

Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19. [PDF]

open access: yesJAMA Netw Open
Ma KC   +50 more
europepmc   +1 more source

Selective Sequestration of Toxic NOx Gases by P‐Doped Graphene: A Density Functional Theory Study

open access: yesAdvanced Physics Research, EarlyView.
P‐doped graphene (P‐grap) is explored as an NOx sensor through DFT simulations. The analysis of its geometry, binding energies, electronic properties, and atom‐in‐molecule characteristics demonstrates that P‐grap is a selective sensor for NOx among a mixture of various gases.
Anwar Ali   +3 more
wiley   +1 more source

Chicken Pulmonary MicroRNAs Targeting the PB2 (Segment 1) of Avian Influenza Virus

open access: yesAnimal Research and One Health, EarlyView.
The PB2 segment of H5N1 is essential for replication and host adaptation. We screened 200 miRNAs and identified five (gga‐miR‐17‐3p, gga‐miR‐29a‐5p, gga‐miR‐1718, gga‐miR‐16c‐5p, and gga‐miR‐1744‐5p) using thermodynamic stability of heteroduplex, seed sequence complementarity, conservation, and accessibility, offering insights into host antiviral ...
Akanksha Choudhary   +7 more
wiley   +1 more source

Most Upper Extremity Injuries in Elite Summer League Baseball Players Occur From Overuse, Affect the Shoulder, and Result in Missed Playing Time

open access: yesArthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To characterize the epidemiology of upper extremity injuries among elite college baseball players in 1 league over 5 seasons. Methods Deidentified arm injury reports were recorded from the 2018, 2019, 2021, 2022, and 2023 Cape Cod Baseball League (CCBL) seasons.
David F. Painter   +6 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy